Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2

被引:17
作者
Huusko, P
Castrén, K
Launonen, V
Soini, Y
Pääkkönen, K
Leisti, J
Vähäkangas, K
Winqvist, R
机构
[1] Univ Oulu, Oulu Univ Hosp, Dept Clin Genet, FIN-90220 Oulu, Finland
[2] Univ Oulu, Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland
[3] Univ Oulu, Oulu Univ Hosp, Dept Pathol, Oulu, Finland
[4] Univ Oulu, Dept Pharmacol & Toxicol, Oulu, Finland
关键词
D O I
10.1016/S0165-4608(98)00258-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in BRCA1 and BRCA2 account for a large portion of the inherited predisposition to breast and ovarian cancer. If runs recently discovered that mutations in these two genes are less common in the Finnish population than expected, Because the genetic background of breast cancer, in particular, is largely obscure, it became necessary to search for mutations in other susceptibility genes. Because seven of our BRCA1 and BRCA2 mutation-negative families fulfilled the criteria of either Li-Fraumeni syndrome (LFS) or Li-Fraumeni-like syndrome (LFL), we decided to screen them for germ-line TP53 mutations in exons 5-8 using a dual-temperature single-strand conformation polymorphism assay (SSCP). Two missense mutations (Asn235Ser and Ty220Cys) were identified. The clinical significance of these findings was evaluated by comparison to previously reported germ-line TP53 mutation data, and by using the tumor loss of heterozygosity (LOH) analysis. In addition, an immunohistochemical analysis of tumor specimens from mutation-positive individuals was performed. Our results suggest that the observed missense mutations confer susceptibility: to cancer, and that germ-line TP53 mutations would therefore explain an additional fraction of hereditary breast cancer in Finland. (C) Elsevier Science Inc., 1999. All rights reserved.
引用
收藏
页码:9 / 14
页数:6
相关论文
共 34 条
[11]  
JOLLY KW, 1994, ONCOGENE, V9, P97
[12]  
Kleihues P, 1997, AM J PATHOL, V150, P1
[13]   Chromosome 11q22.3-q25 LOH in ovarian cancer:: Association with a more aggressive disease course and involved subregions [J].
Launonen, V ;
Stenbäck, F ;
Puistola, U ;
Bloigu, R ;
Huusko, P ;
Kytölä, S ;
Kauppila, A ;
Winqvist, R .
GYNECOLOGIC ONCOLOGY, 1998, 71 (02) :299-304
[14]  
LEHMAN TA, 1991, CANCER RES, V51, P4090
[15]  
LI FP, 1988, CANCER RES, V48, P5358
[16]   SOFT-TISSUE SARCOMAS, BREAST CANCER, AND OTHER NEOPLASMS - A FAMILIAL SYNDROME [J].
LI, FP ;
FRAUMENI, JF .
ANNALS OF INTERNAL MEDICINE, 1969, 71 (04) :747-+
[17]  
LIDEREAU R, 1992, HUM GENET, V89, P250
[18]   GERM LINE P53 MUTATIONS IN A FAMILIAL SYNDROME OF BREAST-CANCER, SARCOMAS, AND OTHER NEOPLASMS [J].
MALKIN, D ;
LI, FP ;
STRONG, LC ;
FRAUMENI, JF ;
NELSON, CE ;
KIM, DH ;
KASSEL, J ;
GRYKA, MA ;
BISCHOFF, FZ ;
TAINSKY, MA ;
FRIEND, SH .
SCIENCE, 1990, 250 (4985) :1233-1238
[19]  
MAZARS GR, 1992, ONCOGENE, V7, P781
[20]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71